Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 18% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: radiationcancertherapysmall cellundergoing
  Phrases that lowered it: maleprostateurinaryphase iiimonotherapy
• Sponsor's past termination rate: 25% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 11.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 77.1% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports before start: 1528 (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases NCT04523207 · started 2020 · scored riskier than 49% of active trials completed
• Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer NCT03124433 · started 2017 · scored riskier than 58% of active trials completed
• Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy NCT02203695 · started 2015 · scored riskier than 95% of active trials completed
• Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy NCT03570827 · started 2018 · scored riskier than 94% of active trials completed
• Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy NCT00528866 · started 2008 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.